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Abstract
Background: There is immunohistochemical evidence to suggest that expression of epidermal
growth factor receptor (EGFR) in primary colorectal adenocarcinoma predicts its expression in
recurrent disease. This study investigates whether postoperative chemotherapy affects the degree
of concordance between EGFR statuses of the two tumors.
Methods: Thirty-three patients were identified from the files of Sunnybrook Health Sciences
Center from July 1994 to June 2005. All patients had resection of their primary tumors and their
distant recurrences. Eighteen patients received postoperative chemotherapy, 3 of which also
received postoperative radiation therapy. Representative primary and recurrent tumor sections
were stained using mouse anti-EGFR antibodies and only membranous staining of malignant cells
was recorded. Results were reported as negative (no staining), 1+ (positivity in <50% of cells) or
2+ (positivity in >50% of cells).
Results: EGFR immunostaining in the 15 patients, who received no postoperative chemotherapy,
was decreased in 3 recurrences, remained the same in 10 and increased in 2. In the group of 18
patients who received postoperative chemotherapy, EGFR immunostaining was decreased in 6
recurrences, remained the same in 9 and increased in 3 (p = 0.6598). In patients who received
postoperative chemotherapy, the odds ratio for a recurrence to show lower levels of EGFR
immunostaining compared to its originally resected primary was 4.75 (CI = 0.94 – 26.73).
Conclusion:  These preliminary data suggest that recurrences following postoperative
chemotherapy are likely to have lower levels of EGFR expression compared to cases who receive
no chemotherapy. Although the difference of immunostaining profiles between the two groups was
not statistically significant, this observation might impact the management of these patients by
targeted biologic therapies and its practical implications need further validation in larger series.
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Background
Epidermal growth factor receptor (EGFR) is a transmem-
brane glycoprotein, which is reported to be overexpressed
in approximately 70 to 75% of colorectal cancer [1]. It
consists of an extracellular ligand-binding domain, a
transmembrane region, and an intracellular tyrosine
kinase domain [2,3]. Its signaling pathways have been
linked to tumor proliferation, invasion, cellular migra-
tion, angiogenesis, and resistance to apoptosis [4]. Cetux-
imab (Erbitux) is a human/murine chimeric antibody
(IgG1) that targets the extracellular domain of EGFR with
high specificity and affinity [5]. Clinical trials in the set-
ting of metastatic colon cancer refractory to chemotherapy
have shown efficacy with modest toxicity, both as a single
agent and in combination with irinotecan [6-8].
The US Food and Drug Administration approved Cetuxi-
mab in February 2004 for use as a third-line therapy in
patients with metastatic colorectal cancer refractory to iri-
notecan. Studies in patients with EGFR expressing tumors
demonstrated a superior response rate and longer time to
progression in those who received Cetuximab [8]. In these
studies, EGFR status was mostly determined by immuno-
histochemical staining of primary tumor samples rather
than from recurrent or metastatic tumors [6-8]. There is
established immunohistochemical evidence to suggest
that EGFR expression in primary colorectal adenocarci-
noma predicts its expression in recurrent disease [9-11].
However, the potential changes in the tumor's EGFR sta-
tus due to postoperative chemotherapy effects have not
been addressed. The question of whether modulation of
EGFR status by chemotherapy can occur has already been
address in other tumors [12]. Induction chemotherapy
has been shown to induce EGFR expression in are cases of
EGFR-negative non-small cell lung cancer. This study
investigates whether postoperative adjuvant therapy
affects the degree of concordance between EGFR statuses
of the primary and recurrent colorectal cancer.
Materials and methods
Specimen selection
During the period of July 1994 – June 2005, 33 colorectal
adenocarcinoma patients with distant recurrence were
captured in our pathology database. Surgical resection of
all primary tumors was performed. Eighteen patients
received postoperative chemotherapy; three of which also
received postoperative radiation therapy. All resected
metastases were metachronous. Liver segmentectomy or
lobectomy was undertaken at a later time for 31 patients
and lung lobectomy for 2 patients to resect their distant
recurrences. All hematoxylin and eosin-stained slides
from the resected primary and recurrent tumors were ret-
rospectively reviewed to confirm the diagnosis and to
select a block for immunohistochemical staining.
Immunohistochemistry
According to our local protocols, all resected tissue speci-
mens were fixed for 24 hours in 10% neutral buffered for-
malin. At the time of the study, the selected paraffin
blocks had been stored for 7 – 122 months (mean = 51, ±
36). Immunostaining was performed on 5-μm-thick for-
malin-fixed, paraffin-embedded tissue sections, using a
Dako Autostainer (DAKO, Carpinteria, CA) according to
the manufacture's specifications. Sections were stained
using mouse anti-EGFR antibodies (Zymed Laboratories,
Inc., San Francisco, CA). The antibody used was clone
31G7 and sections were incubated for 30 minutes at room
temperature at the dilution of 1:100. The antibody manu-
factured by Zymed Laboratories was chosen for the cur-
rent study since this was the antibody employed in our
local laboratory for the past 3 years and since it was one of
the three antibodies equally recommended by the Cana-
dian Consensus Panel on EGFR Testing in Colorectal Can-
cer [13].
Predigestion by pepsin at 37°C for 10 minutes was per-
formed. Positive (ductal carcinoma of the breast) and neg-
ative controls were stained with every run. To avoid any
potential interference by endogenous biotin in liver tis-
sue, the biotin-free detection system, mouse-probe HRP
polymer kit (MACH 3™) by Biocare Medical (Walnut
Creek, CA) was used. Sections were immunostained in
batches and were all processed by a single experienced
immuno-histotechnologist.
Evaluation and analysis
Positive staining was defined as any membranous brown
staining of malignant cells above background level (Fig-
ure 1). Cytoplasmic staining without associated mem-
brane staining was considered as negative. The
immunostaining results were recorded on a three-tier
scale as negative (no staining), 1+ (positivity in <50% of
cells) and 2+ (positivity in >50% of cells). In order to aug-
ment objectivity of our results, intensity of staining was
not included as a reportable variable. Immunostaining of
each of the primary and recurrent tumors was assessed
blindly, without knowledge of the immuno-status of its
counterpart. The clinical data were obtained from the
patient's electronic charts. SAS 8.2 (SAS Institute, Cary,
NC) system was used for data analysis.
Results
Patients ranged in age at the time of primary diagnosis
from 41 to 80 years old (mean = 65.4 ± 10.2). Their clini-
cal data are summarized in Table 1. One patient with stage
I disease and 2 with stage II were suspected to have local
recurrence shortly after resection of their primary tumors
for which they received chemotherapy. Five patients with
stage III and one with stage IV did not receive adjuvantWorld Journal of Surgical Oncology 2006, 4:92 http://www.wjso.com/content/4/1/92
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chemotherapy for a variety of comorbidity reasons. None
of the patients had received EGFR-targeted therapy.
As shown in Table 2, twenty-one (63.6%) of the primary
tumors and 17 (51.5%) of their distant recurrences had
positive EGFR immunostaining. Nineteen of the 33
(57.6%) cases showed the exact degree of immunopositiv-
ity in both primary and recurrent tumors. As shown in this
table, 4 patients had primary EGFR-negative tumors with
EGFR-positive (1+) distant recurrences. Only 2 of these 4
patients received adjuvant chemotherapy. On the other
hand, 2 patients with 2+ primary tumors had EGFR-nega-
tive distant recurrences and both patients received adju-
vant chemotherapy. Also, 6 other patients had 1+ primary
tumor but their recurrences were EGFR-negative. Only 4
of these 6 patients had adjuvant chemotherapy. Accord-
ingly, in patients who received chemotherapy, the switch
from positive to negative occurred in 6 patients and vice
versa in 2 cases. To assess conformity of the two types of
lesions, the weighted Kappa statistics produced a value of
0.44 representing a moderate degree of agreement.
Further comparison between immunostaining of the pri-
mary tumors and their corresponding distant recurrences
showed that in the 15 patients who received no postoper-
ative chemotherapy, EGFR immunopositivity was
decreased in only 3 distant recurrences but remained the
same or increased in 12. In the group of 18 patients who
received postoperative chemotherapy, EGFR immunos-
taining was decreased in 6 recurrences but remained the
same or increased in 12. These results are summarized in
Table 3. Although there was a higher tendency of distant
recurrent tumors to show less EGFR immunostaining in
the postoperative chemotherapy group, the difference
between the two groups tested by Mantel-Haenszel Chi-
square was not statistically significant (p = 0.6598). When
comparing patients who did and did not receive adjuvant
chemotherapy, those who received chemotherapy had an
odds ratio of 4.75 (95% CI = 0.94 – 26.73) of having
decreased EGFR immunostaining compared to those who
did not receive chemotherapy.
Distant recurrence occurred 1 – 59 months (mean 14.9 ±
10.3) following the initial tumor resection. The difference
between the median time-to-recurrence of primary
tumors with the various degrees of staining was not statis-
tically significant as shown by Log-Rank and Wilcoxon
tests.
Discussion
We assessed EGFR status of paired primary and distant
recurrences of colorectal adenocarcinomas in a group of
patients who received postoperative chemotherapy and
compared their results with another group who did not
receive any adjuvant therapy. We reported the results on a
three-tier scale as negative (no staining), 1+ (positivity in
<50% of cells) and 2+ (positivity in >50% of cells). We
have reported earlier that the status of the primary tumor
has a statistically significant predictive relationship to that
of its recurrence when all tumors are collectively analyzed
[10]. When the two groups were separated according to
whether postoperative chemotherapy was administered, it
was noted that recurrences following postoperative chem-
otherapy were approximately 5 times more likely to have
lower levels of EGFR expression. These preliminary results
document a trend which was not recognized earlier and
may impact decision making when managing these
patients with targeted biologic therapies especially since
the anti-EGFR drug Cetuximab is only approved for
patients who fail to respond to first line chemotherapy.
The odds ratio for such recurrent tumors to exhibit lower
levels of EGFR immunostaining compared to their origi-
nally resected primary is 4.75. The influence of postoper-
ative chemotherapy on EGFR immunostaining in this
small patient population was not statistically significant
(p = 0.6598).
Several in vitro studies have shown that tumor cells which
are sensitive to EGFR-targeted therapy, will also respond
to the inhibitory effects of a number of cytotoxic drugs,
which differ in their mechanism of action [14,15]. A
recent study using colorectal cell lines showed that cells
with high constitutive EGFR activity were not only sensi-
tive to anti-EGFR agents but were also more likely to
respond to oxaliplatin and 5-fluorouracil [16]. These find-
ings may suggest that EGFR-positive cell clones within a
colorectal adenocarcinoma may have an intrinsic suscep-
tibility to postoperative chemotherapy due to complex
EGFR immunopositivity in > 50% of cells in a metastatic  colorectal adenocarcinoma to the liver (original magnification  × 200) Figure 1
EGFR immunopositivity in > 50% of cells in a metastatic 
colorectal adenocarcinoma to the liver (original magnification 
× 200).World Journal of Surgical Oncology 2006, 4:92 http://www.wjso.com/content/4/1/92
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and overlapping pathways. Consequently, a recurrent
tumor may tend to include less EGFR-positive cells. The
three-tier scale that we followed in recording our results
allowed us to detect this trend, the statistical significance
of which may need to be established in a larger series.
Since EGFR-selective tyrosine kinase inhibitors are typi-
cally given to patients who have already been on chemo-
therapy, the tendency for a recurrent tumor to include less
EGFR-positive cells especially if validated in larger series,
could influence its sensitivity to this targeted therapy. A
recent report on 16 patients with "EGFR-negative", chem-
otherapy-refractory tumors that responded to Cetuximab
has been published [17]. At the current time, the selection
or exclusion of patients for Cetuximab therapy on the
basis of EGFR immunohistochemical testing remains a
topic for further investigation.
In two previous studies of EGFR expression in colorectal
carcinoma [9,18], the authors attempted reporting on the
intensity of staining as weak, moderate and strong. How-
Table 2: Results of EGFR immunostaining
Primary Distant Recurrence Total
Negative 1+ 2+
Negative 840 1 2
1+ 651 1 2
2+ 2169
Total 16 10 7 33
Negative No staining above the background
1+ Immunopositivity in < 50% of cells
2+ Immunopositivity in > 50% of cells
Table 1: Clinical characteristics
Characteristic Number of patients
Postoperative chemotherapy No postoperative chemotherapy
Sex
Males 11 9
Females 7 6
Primary tumor location
Cecum 3 2
Colon 2 2
Sigmoid colon 7 6
Rectum 6 5
Tumor stage at the time of diagnosis
Stage I 1 0
Stage II 3 9
Stage III 14 5
Stage IV 0 1
Surgery
Right hemicolectomy 3 3
Anterior resection 1 3
Low anterior resection 9 2
Subtotal colectomy 1 0
Pelvic exenteration 0 5
Left hemicolectomy 1 0
Abdomino-perineal resection 2 2
Total proctocolectomy 1 0
Additional therapy
Neoadjuvant chemotherapy 1* 3*
Neoadjuvant radiation therapy 0 6
Postoperative chemotherapy 18 0
Postoperative radiation therapy 3** 0
* Also received neoadjuvant radiation therapy
** Also received postoperative chemotherapyWorld Journal of Surgical Oncology 2006, 4:92 http://www.wjso.com/content/4/1/92
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ever, their statistical analysis of data focused on the overall
status of cases according to the percentage of positive cells
irrespective of the intensity of staining. Therefore, in the
current study we excluded the intensity of staining from
the analysis and restricted our data collection to the per-
centage of positive cells. We believe that including the
intensity of EGFR staining at this particular point in time
while most pathology laboratories are still trying to agree
on the methodology of reporting will add too much sub-
jectivity into this process.
We used the antibody manufactured by Zymed Laborato-
ries in the current study, which was one of the three anti-
bodies equally recommended by The Canadian
Consensus Panel on EGFR Testing in Colorectal Cancer.
This panel is compromised of 12 practicing Canadian
pathologists, who are recognized leaders in this field and
holders of key positions at major Canadian Hospitals.
They met in Toronto, Canada in September 2004 after
reviewing the most recent practices in EGFR testing. The
Panel agreed not to require the use of a specific antibody
of EGFR testing, as there was no evidence in the medical
literature to support the superiority of one antibody over
another. The other two antibodies that were recom-
mended in that meeting were manufactured by Dako
(Mouse EGFR Clone H11 or DakoCytomation EGFR
pharmDx kit) and Ventana (CONFIRM anti-EGFR [3C6]
primary antibody) [13].
According to Atkins et al., [19], EGFR immunopositivity in
colorectal cancer inversely correlates with the storage time
of unstained slides. The authors recommended that spec-
imens should be tested within the first 9 months to avoid
false-negative results. The current is a retrospective study
that specifically investigated whether adjuvant chemo-
therapy could influence the status of EGFR staining in
recurrent colorectal cancer. Therefore, we included pri-
mary and recurrent tumor blocks for comparison with the
understanding that storage might limit staining sensitiv-
ity. Our studied tissues were fixed in 10% neutral buffered
formalin, which added stability of preservation and pH
neutrality. They were stored for the average of 51 months.
Conclusion
Our study shows that 57.6% of all recurrent colorectal
adenocarcinomas will exhibit the same EGFR staining sta-
tus of their primaries. However, patients who receive post-
operative chemotherapy seem to be more likely to have
recurrences with lower levels of EGFR immunostaining.
Our results also showed that EGFR status could switch
from positive to negative as well as from negative to posi-
tive with or without chemotherapy. Although the current
report is limited by the small sample size, it brings up an
observation that may stimulate further investigation,
especially since EGFR-targeted drugs are typically given to
patients who have already been on chemotherapy.
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